Schrodinger, Inc. Common Stock

Sep 1, 2026

▲ +4.3%today

Schrödinger to Present at Morgan Stanley Global Healthcare Conference

Schrödinger, Inc. will participate in the Morgan Stanley 24th Annual Global Healthcare Conference. The management's fireside chat is scheduled for September 14, 2026, at 1:05 p.m. E.T. Investors can access the live presentation through the company's website, which will be archived for 90 days post-event.

Jul 22, 2026

Schrödinger to Announce Second Quarter 2026 Financial Results on August 5

Schrödinger, Inc. plans to announce its second quarter 2026 financial results on August 5, 2026, after market close. A conference call and webcast will follow at 4:30 p.m. ET, accessible via the company's website. This event highlights the company's commitment to investor relations and transparency.

May 5, 2026

Schr dinger Reports First Quarter 2026 Financial Results First Quarter ACV of $28 Million, Representing 12% Growth Continued Momentum in Transition to Hosted Software Licensing Schr dinger to Launch Bunsen, an Agentic AI

Schr dinger, Inc. reported a first quarter 2026 financial result with an annual contract value (ACV) of $28 million, demonstrating a 12% growth. The company announced plans to launch Bunsen, an agentic AI co-scientist, aimed at enhancing molecular discovery workflows. Despite some positives, the overall revenue saw a slight decline of 2%, and software revenue dropped by 21% amid the shift to hosted licensing. The acquisition of Ajax Therapeutics by Lilly, in which Schr dinger holds a 6% equity stake, highlights the company's successful partnerships in the biopharmaceutical sector.

May 4, 2026

Schrödinger to Participate in Upcoming May 2026 Investor Conferences

Schrödinger, Inc. (Nasdaq: SDGR) has announced its participation in several investor conferences scheduled for May 2026. The discussions will be accessible via the company's website and archived for 90 days post-event. Schrödinger is known for its advanced computational platform that aids in drug development and materials design.

May 4, 2026

Schrödinger to Participate in Upcoming Investor Conferences

Schrödinger is set to participate in several upcoming investor conferences. The company aims to engage with investors and discuss its latest developments. Specific details about the conferences or topics of discussion were not provided in the article.

Apr 21, 2026

Schrödinger to Announce First Quarter 2026 Financial Results on May 5

Schrödinger, Inc. (Nasdaq: SDGR) will report its first quarter 2026 financial results on May 5, 2026, after market close. A conference call and webcast will follow at 4:30 p.m. ET, accessible via the company's website. This event highlights the company's commitment to investor engagement and transparency.

Apr 17, 2026

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Schrödinger has reported inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). The details surrounding these grants were not elaborated upon in the article. This announcement is a procedural update related to compliance with Nasdaq regulations.

Schrödinger Reports Fourth Quarter and Full-Year 2025 Financial Results

Schrödinger, Inc. reported a total revenue of $256 million for 2025, with a notable 23% growth. The company is transitioning to a hosted software model to enhance revenue predictability, despite expecting short-term declines in software revenue. Looking ahead, Schrödinger aims to achieve positive adjusted EBITDA by the end of 2028, supported by its innovative platform and strong customer engagement.

Feb 18, 2026

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - February 18, 2026

Schrödinger, Inc. has announced the granting of stock options and restricted stock units to newly hired employees as part of its 2021 Inducement Equity Incentive Plan. The grants, totaling 9,600 stock options and 18,250 RSUs, were made to incentivize acceptance of employment. The stock options have a ten-year term and vest over four years, while the RSUs also vest over a similar period.

Feb 12, 2026

▼ -5.6%on this newsshared move

Schrödinger to Announce Fourth Quarter and Full-Year 2025 Financial Results on February 25

Schrödinger, Inc. will announce its fourth quarter and full-year 2025 financial results on February 25, 2026, after market close. A conference call and webcast will follow at 4:30 p.m. ET. The event will be accessible via the company's website and archived for 90 days. Schrödinger focuses on molecular discovery through its advanced computational platform.

Jan 13, 2026

Schrödinger Provides Update on Progress Across the Business and Outlines 2026 Strategic Priorities

Schrödinger, Inc. has provided an update on its business progress for 2025 and outlined strategic priorities for 2026. The company aims to enhance its physics+AI computational platform and expand its drug discovery collaborations. Notably, new agreements with Lilly and Manas AI are expected to bolster its capabilities in addressing data scarcity in molecular discovery.

Jan 9, 2026

Schrödinger Partners with Lilly to Make TuneLab Platform Available in LiveDesign

Schrödinger, Inc. has announced a partnership with Eli Lilly to integrate the TuneLab platform into its LiveDesign informatics system. This collaboration is intended to enhance drug discovery by providing advanced AI capabilities to biotech companies. Schrödinger's platform aims to democratize access to computational tools, facilitating more efficient workflows in drug development.

Nov 5, 2025

Schr dinger Reports Third Quarter 2025 Financial Results Third Quarter Total Revenue of $54.3 Million, Software Revenue of $40.9 Million Updates 2025 Financial Guidance New York

Schr dinger, Inc. reported a solid third quarter for 2025, achieving total revenues of $54.3 million and software revenues of $40.9 million, reflecting a growth of 54% and 28%, respectively. However, the company revised its software revenue growth guidance down from 10-15% to 8-13% due to expectations around pharma collaborations. Despite a reduction in net loss from the previous year, the company faced reduced other income and continues to adjust its operational strategy for improved efficiency. Notably, they are progressing in their Phase 1 studies for SGR-3515 and SGR-1505, with initial clinical data expected in 2026.

Aug 6, 2025

Schr dinger Reports Second Quarter 2025 Financial Results Second Quarter Total Revenue of $54.8 Million, Software Revenue of $40.5 Million Maintains Full Year 2025 Revenue Growth Guidance and Lowers Operating Expense Gui

Schr dinger, Inc. reported second quarter financial results with a total revenue of $54.8 million, representing a 16% increase from the previous year. The company also confirmed its full year 2025 revenue growth guidance while lowering its operating expenses. Notably, initial data for the MALT1 inhibitor SGR-1505 demonstrated good tolerability and clinical activity. However, the company incurred a net loss of $43.2 million, although this was a decrease compared to the same period last year.

May 7, 2025

SDGRPhases

Schr dinger Reports Strong First Quarter 2025 Financial Results First Quarter Total Revenue of $59.6 Million, Software Revenue of $48.8 Million Initial SGR-1505 Phase 1 Clinical Data to be Presented in June Maintains 202

Schr dinger, Inc. announced strong financial results for the first quarter of 2025, with total revenue reaching $59.6 million, up 63% year-over-year. The company saw substantial growth in software revenue and drug discovery revenue, largely attributed to early renewals and collaborative programs. Despite this positive financial performance, Schr dinger reported a net loss of $59.8 million, which is an increase from the previous year's loss. The company maintains its financial guidance for 2025 and is looking forward to presenting initial clinical data for SGR-1505 in June.

Apr 11, 2025

▲ +27.4%on this news· ran to +38% by day 1

SUPREME COURT OF THE STATE OF NEW YORK COUNTY OF NEW YORK ARNAT ABZHANOV, derivatively on behalf of SCHRODINGER, INC., Plaintiff, v. MICHAEL LYNTON, JEFFREY CHODAKEWITZ, RICHARD A. FRIESNER, GARY GINSBERG, ROSANA KAPELLE

A derivative action has been filed against members of the Board of Schr dinger, Inc. for alleged breaches of fiduciary duty regarding excessive compensation. A proposed settlement has led to a series of corporate governance reforms intended to benefit the company and its stockholders. These reforms include a new compensation policy that limits board pay and incorporates annual assessments by an independent compensation consultant. A hearing is scheduled for June 18, 2025, to discuss the settlement details.

Feb 26, 2025

Schr dinger Reports Strong Fourth Quarter and Full-Year 2024 Financial Results Achieved 2024 Software Revenue of $180.4 Million, a 13.3% Increase Over 2023 Expects Software Revenue Growth of 10% to 15% and Drug Discovery

Schr dinger, Inc. reported its financial results for the fourth quarter and full year of 2024, highlighting a 13.3% increase in software revenue compared to 2023. However, the total revenue for the year decreased by 4.2%, leading to a substantial net loss. The company has announced an expansion of its collaboration with Eli Lilly and is expecting to grow software revenue by 10% to 15% and drug discovery revenue in 2025. Schr dinger aims to continue leveraging its validated computational methods within its partnerships and proprietary programs.

Schr dinger Reports Third Quarter 2024 Financial Results Schr dinger to Receive $150 Million Upfront for New Multi-Target Collaboration with Novartis Third Quarter Total Revenue of $35.3 Million, Software Revenue of $31.

Schr dinger, Inc. announced its financial results for Q3 2024, highlighting a new multi-target collaboration with Novartis worth $150 million upfront and potential milestone payments totaling $2.3 billion. While total revenue declined by 17% year-over-year to $35.3 million, software revenue showed a positive trend, increasing by 10% to $31.9 million. Despite increasing operating expenses and a net loss of $38.1 million, the company remains optimistic about future growth and upcoming data from its proprietary pipeline.

Jul 31, 2024

Schr dinger Reports Strong Second Quarter 2024 Financial Results Second Quarter Total Revenue of $47.3 Million, Software Revenue of $35.4 Million Launches Major Initiative to Expand Application of Computational Tools for

Schr dinger, Inc. (SDGR) announced strong financial results for the second quarter of 2024, achieving total revenue of $47.3 million, a 35% increase from the previous year. Software revenue growth was notable at 21%, reflective of greater adoption of their computational tools. Despite this success, the company reported a net loss of $54 million and increased operating expenses, highlighting ongoing financial challenges. Additionally, Schr dinger launched a new initiative focused on predictive toxicology, aimed at improving drug development outcomes, supported by a grant from the Bill Melinda Gates Foundation.

May 1, 2024

SDGRFDA Updates

Schr dinger Reports First Quarter 2024 Financial Results First Quarter Total Revenue of $36.6 Million, Software Revenue of $33.4 Million Announces FDA Clearance of Investigational New Drug Application for SGR-3515, a Nov

Schr dinger, Inc. has reported its financial results for the first quarter of 2024, with total revenue declining to $36.6 million, a significant drop from $64.8 million the previous year. However, the company announced FDA clearance of its IND application for SGR-3515, a novel Wee1 Myt1 inhibitor, and expects to initiate clinical trials soon. Despite the revenue decline and a net loss of $54.7 million, the software segment showed a modest growth in revenue, and the company is maintaining its financial guidance for the year.

Feb 28, 2024

▼ -5.2%on this news· ran to -24% by day 3

Schr dinger Reports Strong Fourth Quarter and Full-Year 2023 Financial Results Achieved Fourth Quarter Software Revenue of $68.7 Million, a 44% Increase Over Fourth Quarter 2022 Delivered 20% Annual Total Revenue Growth,

Schr dinger, Inc. reported strong financial results for the fourth quarter and full-year 2023, highlighted by substantial revenue growth across its software segment. The company achieved $68.7 million in software revenue during the fourth quarter, representing a 44% increase year-over-year, and a total revenue of $216.7 million for the year, marking a 19.7% rise. Despite these positive results, the firm also reported a net loss of $30.7 million for the fourth quarter, a slight increase from the previous year. Looking forward, Schr dinger anticipates software revenue growth of 6% to 13% in 2024.

Nov 1, 2023

Schr dinger Reports Third Quarter 2023 Financial Results Delivers Third Quarter Total Revenue of $42.6 Million Maintains Full-Year 2023 Revenue Guidance Continued Progress for SGR-1505, Healthy Volunteer Data Expected in

Schr dinger, Inc. reported financial results for Q3 2023, highlighting total revenue of $42.6 million, a 15.1% increase from the previous year. The company maintains its positive financial outlook for the remainder of 2023, with expected software revenue growth of 15% to 18%. Progress continues with ongoing Phase 1 studies for SGR-1505 and SGR-2921, as well as the announcement of the PRMT5-MTA discovery program. However, the company also reported a $62.0 million net loss, an increase from the previous year's loss.

Aug 2, 2023

SDGRFDA Updates

Schr dinger Reports Second Quarter 2023 Financial Results Announces IND Clearance for CDC7 Inhibitor SGR-2921, Continued Progress for MALT1 Inhibitor SGR-1505 Delivers Second Quarter Total Revenue of $35.2 Million Raises

Schr dinger, Inc. reported its financial results for Q2 2023, posting a total revenue of $35.2 million, down from last year. The company announced FDA clearance for its CDC7 inhibitor SGR-2921 and ongoing advancements for its MALT1 inhibitor SGR-1505, with Phase 1 studies expected to yield preliminary data soon. Despite a rise in operating expenses, Schr dinger's cash reserves increased significantly year-over-year. The company has also revised its revenue expectations for drug discovery, reflecting strategic adjustments to its pipeline progress and collaboration timelines.

May 4, 2023

SDGRPhases

Schr dinger Reports Strong First Quarter 2023 Financial Results Delivered First Quarter Total Revenue of $64.8 Million, Driven by Strong Drug Discovery Revenue of $32.6 Million Reports First Subjects Enrolled in Both Ong

Schr dinger, Inc. reported robust financial results for Q1 2023, achieving total revenue of $64.8 million, a 33% increase from the previous year. Significant contributions were made from both software and drug discovery efforts, with drug discovery revenue nearly doubling due to a $25 million milestone payment from BMS. The company has initiated Phase 1 clinical studies for its MALT1 inhibitor, SGR-1505, and continues to progress multiple pipeline programs. Additionally, Schr dinger's cash position has been strengthened by approximately $147.3 million following a distribution from Nimbus, indicating a solid financial outlook moving forward.

Feb 28, 2023

Schr dinger Reports Strong Fourth Quarter and Full-Year 2022 Financial Results Delivered 31% Annual Total Revenue Growth, with Total Revenue of $181.0 Million Achieved Fourth Quarter Software Revenue of $47.8 Million, a

Schr dinger, Inc. reported strong financial results for Q4 and full-year 2022, achieving a total revenue growth of 31% to $181 million. The rise in software revenue by 24% reflects increased adoption of their computational physics platform despite broader economic challenges. Schr dinger anticipates continued revenue growth and reduced cash burn for 2023, supported by multiple successful collaborations and promising new drug candidates. However, the company faced significant increases in operating expenses and posted a net loss of $149.2 million for the year.

Nov 3, 2022

Schr dinger Reports Third Quarter 2022 Financial Results Total Revenue Growth of 24 Percent Over Third Quarter of 2021, Driven by Continued Progress Across Drug Discovery Portfolio Full-Year 2022 Revenue Guidance Range N

Schr dinger Reports Third Quarter 2022 Financial Results Total Revenue Growth of 24 Percent Over Third Quarter of 2021, Driven by Continued Progress Across Drug Discovery Portfolio Full-Year 2022 Revenue Guidance Range Narrowed with Mix Shifting Toward Drug Discovery Phase 1 C

Aug 4, 2022

Schr dinger Reports Second Quarter 2022 Financial Results Software Revenue of $30.0 Million, a 25 Percent Increase Over Second Quarter of 2021 ; Total Revenue of $38.5 Million, up 29 Percent Over Second Quarter of 2021 C

Schr dinger Reports Second Quarter 2022 Financial Results Software Revenue of $30.0 Million, a 25 Percent Increase Over Second Quarter of 2021; Total Revenue of $38.5 Million, up 29 Percent Over Second Quarter of 2021 Company Maintains Full-Year 2022 Financial Outlook Phase 1

Jun 16, 2022

SCHRÖDINGER, INC. 2022 EQUITY INCENTIVE PLAN 1. Purpose The purpose of this 2022 Equity Incentive Plan (the Plan ) of Schr dinger, Inc., a Delaware corporation (the Company ), is to advance the interests of the Comp

EQUITY INCENTIVE PLAN The purpose of this 2022 Equity Incentive Plan (the Plan ) of Schr dinger, Inc., a Delaware corporation (the Company ), is to advance the interests of the Company s stockholders by enhancing the Company s ability to attract, retain and motivate persons who

May 4, 2022

Schr dinger Reports First Quarter 2022 Financial Results Software Revenue of $3 3 . 1 Million, a 26 Percent Increase O ver First Quarter of 2021 ; Total Revenue of $ 48.7 Million, up 51 Percent Over First Quarter of 2021

Schr dinger Reports First Quarter 2022 Financial Results Software Revenue of $33.1 Million, a 26 Percent Increase Over First Quarter of 2021; Total Revenue of $48.7 Million, up 51 Percent Over First Quarter of 2021 Company Maintains Full-Year 2022 Financial Outlook Internal Pi

Feb 24, 2022

▲ +10.3%on this news· ran to +45% by day 3

Schr dinger Reports Financial Results for the Fourth Quarter and Full Year 2021 Delivered Strong Fourth Quarter, with Software Revenue of $38.6 Million, a 55 Percent Increase over Fourth Quarter of 2020 Full Year 2021 To

Schr dinger Reports Financial Results for the Fourth Quarter and Full Year 2021 Delivered Strong Fourth Quarter, with Software Revenue of $38.6 Million, a 55 Percent Increase over Fourth Quarter of 2020 Full Year 2021 Total Revenue of $137.9 Million, up 28 Percent Year-over-Yea

Nov 10, 2021

Schr dinger Reports Third Quarter 2021 Financial Results and Provides Company Update Third Quarter Total Revenue of $29.9 Million, Up 16 Percent Year-Over-Year; Software Revenue of $24.3 Million Recent Collaboration with

Schr dinger Reports Third Quarter 2021 Financial Results and Provides Company Update Third Quarter Total Revenue of $29.9 Million, Up 16 Percent Year-Over-Year; Software Revenue of $24.3 Million Recent Collaboration with Centessa Pharmaceuticals Subsidiary, Orexia Therapeutics,

Schr dinger Reports Second Quarter 2021 Financial Results and Provides Company Update Second Quarter Total Revenue of $29.8 Million, Up 29 Percent Year-Over-Year; Software Revenue of $24.1 Million, Up 15 Percent Year-Ove

Schr dinger Reports Second Quarter 2021 Financial Results and Provides Company Update Second Quarter Total Revenue of $29.8 Million, Up 29 Percent Year-Over-Year; Software Revenue of $24.1 Million, Up 15 Percent Year-Over-Year; Company Maintains Full-Year 2021 Financial Outlook

May 11, 2021

Schr dinger Reports First Quarter 2021 Financial Results and Provides Company Update First quarter total revenue of $32.1 million, up 23 percent year-over-year; Software revenue of $26.3 million, up 11 percent year-over-

Schr dinger Reports First Quarter 2021 Financial Results and Provides Company Update First quarter total revenue of $32.1 million, up 23 percent year-over-year; Software revenue of $26.3 million, up 11 percent year-over-year Expanded agreement with AstraZeneca; New agreement wi

Mar 23, 2021

Transforming Discovery of Therapeutics and Materials

Transforming Discovery of Therapeutics and Materials March 23, 2021 Note and Disclaimer This presentation contains certain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties.

Mar 4, 2021

Schr dinger Reports Financial Results for the Fourth Quarter and Full Year 2020 and Provides Outlook for 2021 Total revenue of $108.1 million in 2020, up 26 percent year-over-year Software revenue of $92.5 million in 202

Schr dinger Reports Financial Results for the Fourth Quarter and Full Year 2020 and Provides Outlook for 2021 Total revenue of $108.1 million in 2020, up 26 percent year-over-year Software revenue of $92.5 million in 2020, up 39 percent year-over-year Strong financial position

Nov 12, 2020

Schr dinger, Inc. Reports Third Quarter 2020 Financial Results and Business Update Total revenue of $25.8 million, up 29% year-over-year; Software revenue of $22.9 million, up 42% year-over-year Raised $325.6 million net

Schr dinger, Inc. Reports Third Quarter 2020 Financial Results and Business Update Total revenue of $25.8 million, up 29% year-over-year; Software revenue of $22.9 million, up 42% year-over-year Raised $325.6 million net proceeds in equity financing Presenting data on our MAL

Aug 10, 2020

Schr dinger, Inc. Reports Second Quarter 2020 Financial Results and Business Updates Total revenue of $23.1 million, up 21% year-over-year Software revenue of $20.9 million, up 44% year-over-year New strategic agreements

Schr dinger, Inc. Reports Second Quarter 2020 Financial Results and Business Updates Total revenue of $23.1 million, up 21% year-over-year Software revenue of $20.9 million, up 44% year-over-year New strategic agreements with Thermo Fisher and Viva Biotech Rapid progress acro

Jun 12, 2020

SCHRÖDINGER Transforming Discovery of Therapeutics and Materials Cautionary Note and Disclaimer This presentation contains certain forward-looking statements within the meaning of the U.S. Private Securities Litigat

Transforming Discovery of Therapeutics and Materials Cautionary Note and Disclaimer contains certain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, oth

May 13, 2020